VRTX
Vertex Pharmaceuticals Inc
BIOTECHNOLOGY · HEALTHCARE
Vertex Pharmaceuticals Inc. is a leading biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development of innovative therapies for serious diseases, primarily cystic fibrosis (CF). Renowned for its pioneering work in CF treatments, Vertex has made significant stri...
$444.93
-0.03% ($0.12)
Volume
924,129
52W High
$507.92
52W Low
$362.50
Market Cap
$108.53B
What to Watch This Quarter
Based on historical dataConsensus EPS
$4.71
Whisper EPS
$4.88
3.5% above consensus
Last Quarter
$4.47
Current Streak
3 Beats
Avg Surprise (4Q)
+2.28%
Next Earnings Report
Reports in 49 days
Price Chart
EPS History: Consensus vs Actual
Last 12 quartersPrice Movement Around Earnings
Q1 2026
May 5, 2026
1-Day:
+0.78%
Q1 2026
May 4, 2026
1-Day:
-1.28%
Q1 2026
Mar 31, 2026
1-Day:
+0.16%
Q4 2025
Feb 12, 2026
1-Day:
+5.69%
5-Day:
+2.65%
Revenue & Financial Performance
Revenue Whisper
$3.12B
TWN Proprietary Estimate
Last Quarter Revenue
$2.99B
+7.8% YoY
Gross Margin
86.9%
Net Margin: 34.5%
| Quarter | Revenue | YoY Growth | Gross Margin | Op Margin | Net Income |
|---|---|---|---|---|---|
| Q1'26 | $2.99B | +7.8% | 86.9% | 38.1% | $1.03B |
| Q4'25 | $3.23B | +10.8% | 85.6% | 40.3% | $1.19B |
| Q3'25 | $3.08B | +11.0% | 86.5% | 38.6% | $1.08B |
| Q2'25 | $2.96B | +12.1% | 86.3% | 38.8% | $1.03B |
| Q1'25 | $2.77B | +3.1% | 86.9% | 22.8% | $646.3M |
| Q4'24 | $2.91B | +15.7% | 85.5% | 35.2% | $913.0M |
| Q3'24 | $2.77B | +11.6% | 85.8% | 40.3% | $1.05B |
| Q2'24 | $2.65B | +6.1% | 85.9% | -132.9% | -$3.59B |
Company Information
Symbol
VRTX
Company
Vertex Pharmaceuticals Inc
Market Cap
$108.53B
Sector
HEALTHCARE
Next Earnings
Aug 3, 2026
Also Reporting Soon
Companies reporting earnings around the same time as VRTX
HEALTHCARE Stocks
Other healthcare companies with earnings data
More in BIOTECHNOLOGY
Compare VRTX with competitors
Side-by-side earnings comparison